Difference Between Left-Sided and Right-Sided Colorectal Cancer: A Focused Review of Literature
Open accessThe DOI matches its Crossref record; 113 of the 113 references it cites were found in a registry or an index.
Abstract
Colorectal cancer is the third most common cancer worldwide with a high mortality rate at the advanced stages. However, colorectal cancer is not a single type of tumor; its pathogenesis depends on the anatomical location of the tumor and differs between right side and left side of the colon. Tumors in the proximal colon (right side) and distal colon (left side) exhibit different molecular characteristics and histology. In the right-sided tumors, mutations in the DNA mismatch repair pathway are commonly observed; and these tumors generally have a flat histology. In the left-sided tumors, chromosomal instability pathway-related mutations, such as KRAS, APC, PIK3CA, p53 mutations are observed and these tumors demonstrate polypoid-like morphology. Therapy responses are totally different between these tumor entities. Left-sided colorectal cancer (LCRC) patients benefit more from adjuvant chemotherapies such as 5-fluorouracil (5-FU)-based regimes, and targeted therapies such as anti- epidermal growth factor receptor (EGFR) therapy, and have a better prognosis. Right-sided colorectal cancer (RCRC) patients do not respond well to conventional chemotherapies, but demonstrate more promising results with immunotherapies because these tumors have high antigenic load. For the development of effective therapy regimes and better treatment options, it is essential to evaluate right-sided and left-sided tumors as separate entities, and design the therapy regime considering the differences between these tumors. Gastroenterol Res. 2018;11(4):264-273 doi: https://doi.org/10.14740/gr1062w
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Right-sided tumors more commonly exhibit DNA mismatch repair deficiencies, while left-sided tumors often have mutations in KRAS, APC, PIK3CA, and p53 [30].”
From Update on Targeted Therapy and Immunotherapy for Metastatic Colorectal Cancer (2024) · cites this paper as [30]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012
Ferlay, J., Soerjomataram, I., Dikshit, R., Eser, S., Mathers, C., Rebelo, M., Parkin, D. M., Forman, D., & Bray, F. (2015) · International Journal of Cancer · doi:10.1002/ijc.29210 · Cited by 28,766
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838 · cited 1×
“highly use these regulators as an anti-tumor immune response [82, 83].”
BackgroundA genetic model for colorectal tumorigenesis
Fearon, E. R., & Vogelstein, B. (1990) · Cell · doi:10.1016/0092-8674(90)90186-i · Cited by 12,132 · cited 1×
“In this model, carcinogenesis begins with the inactivation or deletion of adenomatous polyposis coli (APC) tumor suppressor gene, followed by the activation of Kirsten ras homolog (KRAS) oncogene, the inactivation of p53 tumor suppressor gene and other mutations [47, 48].”
MethodPD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377
Comprehensive molecular characterization of human colon and rectal cancer
The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11252 · Cited by 8,499
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945 · cited 1×
“Metastatic melanoma is one of the tumors with high immunogenic load and melanoma patients are highly benefiting from anti-CTLA-4 and anti-PD-1 therapies [87, 88].”
BackgroundGenetic Alterations during Colorectal-Tumor Development
Vogelstein, B., Fearon, E. R., Hamilton, S. R., Kern, S. E., Preisinger, A. C., Leppert, M., Smits, A. M. M., & Bos, J. L. (1988) · New England Journal of Medicine · doi:10.1056/nejm198809013190901 · Cited by 6,728 · cited 1×
“In this model, carcinogenesis begins with the inactivation or deletion of adenomatous polyposis coli (APC) tumor suppressor gene, followed by the activation of Kirsten ras homolog (KRAS) oncogene, the inactivation of p53 tumor suppressor gene and other mutations [47, 48].”
MethodType, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome
Galon, J., Costes, A., Sanchez-Cabo, F., Kirilovsky, A., Mlecnik, B., Lagorce-Pagès, C., Tosolini, M., Camus, M., Berger, A., Wind, P., et al. (2006) · Science · doi:10.1126/science.1129139 · Cited by 6,516 · cited 4×
“Presence of T cells in these tumors is associated with better prognosis and less frequent metastasis [12, 13, 24].”
BackgroundInfluentialImmune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy
Topalian, S. L., Drake, C. G., & Pardoll, D. M. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.03.001 · Cited by 4,229 · cited 1×
“Interestingly, tumor infiltrating lymphocytes express high level of PD-L1, which is thought to be a result of chronic stimulation because of the neoantigen load [86].”
Background
Cited by
Items 301–400 of 581
Bouriat, K., Cherif, S., Sellami, S., Dref, M., Krati, K., Meriem, M. E., Antri, S. E., Amine, A., & Rais, H. (2022) · Journal of Pure and Applied Microbiology · doi:10.22207/jpam.16.1.75 · Cited by 3
Radioembolisation of liver metastases
Boshell, D., & Bester, L. (2023) · Journal of Medical Imaging and Radiation Oncology · doi:10.1111/1754-9485.13549 · Cited by 4
“4 Primary tumours arising from different regions of the colon are clinically and molecularly distinct, 7,8 and multiple subgroups of mCRC exist.”
BackgroundSerum Cytokine and miRNA Levels Are Differently Expressed in Right- and Left-Sided Colon Cancer
Nunzio, V. D., Donghia, R., Pesole, P. L., Coletta, S., Calò, N., & Notarnicola, M. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12185986 · Cited by 3
“In particular, right-sided colon cancers are characterized by high immunogenicity and a worse prognosis [3,51].”
BackgroundColorectal Oncologic Emergencies
Sullivan, J., Donohue, A. K., & Brown, S. R. (2023) · Surgical Clinics of North America · doi:10.1016/j.suc.2023.12.003 · Cited by 4
Colorectal cancer disease profile and treatment patterns at an urban tertiary hospital in Rwanda
Baldwin, M., Niyibizi, B. A., Rangira, D., Rangira, B., Kazindu, M., Seifu, D., Stefan, C. D., Rugengamanzi, E., & Manirakiza, A. V. C. (2024) · ecancermedicalscience · doi:10.3332/ecancer.2024.1687 · Cited by 4
Dallavilla, T., Galié, S., Sambruni, G., Borin, S., Fazio, N., Romario, U. F., Manzo, T., Nezi, L., & Schaefer, M. H. (2024) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2024.167311 · Cited by 3
“Chromosomal amplification or loss is a common CRC feature primarily affecting left-sided cancers [2].”
InfluentialJo, S. J., Kim, J. M., Shin, J. K., Rhu, J., Huh, J. W., Choi, G., & Joh, J. (2024) · Annals of Surgical Treatment and Research · doi:10.4174/astr.2024.107.5.264 · Cited by 3
“While numerous factors influenced survival in CRC, several studies have reported on the concept of ‘sidedness’, which refers to differences in survival based on the location of the primary tumor [16-19].”
BackgroundPratikna, A. M., Rivai, M. I., Suswita, R., Putra, A. E., Rachman, I. A., & Suchitra, A. (2025) · Annals of Coloproctology · doi:10.3393/ac.2024.00346.0049 · Cited by 3
“The etiology of right-sided colon cancer is highly complex, involving both genetic and environmental factors [5].”
Issa, M., Sultana, E., Hamid, M., Mohamedahmed, A. Y., Albendary, M., Zaman, S., Bhandari, S., Ball, W., Narayanasamy, S. N., Thomas, P. F., et al. (2025) · International Journal of Colorectal Disease · doi:10.1007/s00384-025-04858-1 · Cited by 3
Prognostic Factors for Survival in Transverse Colon Cancers
Küçükarda, A., Gökyer, A., Sayın, S., Gökmen, İ., Özcan, E., Köstek, O., Hacıoğlu, M. B., Uzunoğlu, S., Çiçin, İ., & Erdoğan, B. (2021) · Journal of Gastrointestinal Cancer · doi:10.1007/s12029-021-00675-1 · Cited by 3
Recent Understanding of Colorectal Cancer Treatment
Jeong, K.-Y. (2022) · IntechOpen eBooks · doi:10.5772/intechopen.100844 · Cited by 3
Primary site and treatment impact in unresectable metastatic colorectal cancer
Krishnan, T., Wang, F., Karapetis, C. S., Roy, A. C., & Price, T. J. (2023) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2023.2208353 · Cited by 3
Expression Pattern of DAB Adaptor Protein 2 in Left- and Right-Side Colorectal Carcinoma
Šustić, I., Racetin, A., Vukojević, K., Benzon, B., Tonkić, A., Šundov, Ž., Puljiz, M., Durdov, M. G., & Filipović, N. (2023) · Genes · doi:10.3390/genes14071306 · Cited by 3
“Further, different metabolic characteristics, bile acid exposure and molecular biology are mentioned [6].”
BackgroundInfluentialColonic actinomycosis presenting as a palpable colonic mass with normal colonic mucosa
Charernsuk, M., Tunruttanakul, S., Tunruttanakul, R., & Chareonsil, B. (2021) · Journal of Surgical Case Reports · doi:10.1093/jscr/rjab381 · Cited by 3
“An intra-abdominal mass usually raises concerns for patients and physicians; mainly when the mass originates from the colon, as is often the case with cancer [9].”
BackgroundStage-specific survival differences between colon cancer subsites: a population-based study
Reima, H., Soplepmann, J., & Innos, K. (2021) · Acta Oncologica · doi:10.1080/0284186x.2021.1987515 · Cited by 3
Molecular Pathways, Targeted Therapies, and Proteomic Investigations of Colorectal Cancer
Yerlikaya, A., & Zeren, S. (2021) · Current Molecular Medicine · doi:10.2174/1566524022666211224120614 · Cited by 4
Lim, D. M., Kang, J., Woo, S.-Y., Choi, H.-S., Kwon, M., Kim, J., Park, H. R., Jung, K., Baryawno, N., Kim, H., et al. (2022) · PubMed · Cited by 4
Human NINEIN polymorphism at codon 1111 is associated with the risk of colorectal cancer
Yasuda, Y., Sakai, A., Ito, S., Sasai, K., Ishizaki, A., Okano, Y., Kawahara, S., Jitsumori, Y., Yamamoto, H., Matsubara, N., et al. (2020) · Biomedical Reports · doi:10.3892/br.2020.1352 · Cited by 3
Colorectal cancer demographics in Barbados
Griffith, S. P., Padmore, G. M., Phillips, E., Ramkissoon, S. C., Moore, S., Walkes, K., Gohar, A. A., & Cawich, S. O. (2021) · Medicine International · doi:10.3892/mi.2021.2 · Cited by 3
“There is consensus on the definition of geographic origin of the primary (3,24).”
BackgroundRais, G., Boutaggount, F., Mokfi, R., Maskrout, M., Bennour, S., Senoussi, C., Rais, F., & Lahlou, L. (2024) · Cureus · doi:10.7759/cureus.56733 · Cited by 2
“Conversely, left-sided tumors often present with mutations in the chromosomal instability pathway, involving mutations in KRAS , APC , PIK3CA , and p53 , and have a polypoid-like morphology [15].”
BackgroundZorzi, M., Calciano, L., Gennaro, N., Memo, L., Rizzato, S., Stocco, C. F., Urso, E. D. L., Negro, S., Spolverato, G., Pucciarelli, S., et al. (2024) · BMJ Open Gastroenterology · doi:10.1136/bmjgast-2024-001434 · Cited by 3
Elgohary, S. A., Abdelsalam, S. M., & Khaled, R. S. T. (2023) · Egyptian Journal of Pathology · doi:10.4103/egjp.egjp_7_23 · Cited by 2
Mohammed, D. S., & Hasan, I. A. (2025) · Indian Journal of Pathology and Microbiology · doi:10.4103/ijpm.ijpm_383_24 · Cited by 2
Zhao, W., Qiu, Y., Bai, N., He, C., Yin, J. C., Xu, Q., Jian, K., Jia, B., Jiang, L., & Liang, F. (2026) · Cancer Medicine · doi:10.1002/cam4.71534 · Cited by 2
“These tumors are typically categorized as consensus molecular subtype-1 (CMS-1) and have shown improved response to immunotherapy, likely due to higher tumor mutational burden (TMB) [15].”
InfluentialJurescu, A., Dema, A. L. C., Tăban, S. M., Barna, R. A., Văduva, A., Viţa, O. C., Cornea, R. F., Lăzureanu, C., Mureşan, A. M., Cornianu, M., et al. (2026) · Life · doi:10.3390/life16020242 · Cited by 3
Cozac-Szőke, A.-R., Cotoi, O. S., Mauer, U., Steinestel, K., & Arndt, A. (2026) · Cancers · doi:10.3390/cancers18040666 · Cited by 3
del Prado-Montero, J., Cantero-Cid, R., Guevara-Martínez, J., Lozano‐Rodríguez, R., Cueto, F. J., María-Diez, G. S. D. S., Terrón‐Arcos, V., Moret, R., Serrano, E. D., Córdoba, L., et al. (2026) · Cellular Oncology · doi:10.1007/s13402-026-01174-w · Cited by 2
“Significant molecular, histological, and clinical distinctions have been described between right-sided (proximal) and left-sided (distal) colon cancers, as well as between colonic and rectal tumours [ 9 , 10].”
Gholami, S., Saeed, A., Baca, Y., Hinton, A. C., Demyan, L., Abidalhassan, M. F., Xiu, J., Manji, G. A., Seeber, A., Weinberg, B. A., et al. (2026) · BMJ Oncology · doi:10.1136/bmjonc-2025-001003 · Cited by 3
“Time on treatment was also higher in the CXCR4 high cohort compared with the CXCR4 low cohort (5.1 months vs 3.5 months, HR=1.21, 95% CI 1.002 to 1.465, p=0.051) (online supplemental figure 5).”
InfluentialChou, C.-L., Lin, C., Li, W.-S., Lee, S., Kuo, Y., Shiue, Y., Li, C., Lai, H.-Y., & Yang, C. (2026) · Laboratory Investigation · doi:10.1016/j.labinv.2026.106128 · Cited by 2
Lai, T. T., Ishida, M., Kosaka, H., Matsui, K., Matsushima, H., Yamamoto, H., Kiguchi, G., Nguyen, K. V., Inoue, K., Takada, M., et al. (2024) · Cancers · doi:10.3390/cancers16223827 · Cited by 2
Zlatović, J. J., Bevanda, M., Dobrić, V. T., Curić, Z., Marijanović, I., Karaga, M., Skelin, M., Tomić, S., Dilber, I., & Omrčen, T. (2026) · Biomedicines · doi:10.3390/biomedicines14020312 · Cited by 2
Wong, V., Lee, M., Wong, R., Tie, J., Shapiro, J. D., Desai, J., Nott, L. M., Steel, S. A., Burge, M., Ma, B. B. Y., et al. (2021) · Targeted Oncology · doi:10.1007/s11523-021-00793-7 · Cited by 2
Molecular Oncology in Management of Colorectal Cancer
Vemala, R. N. G., Katti, S. V., Sirohi, B., Manikandan, D., & Nandakumar, G. (2021) · Indian Journal of Surgical Oncology · doi:10.1007/s13193-021-01289-6 · Cited by 2
“Left-sided CRCs are more likely to display CIN [18], and as in vitro”
BackgroundInfluentialFluoropyrimdine therapy induced alterations in interleukins expression in colorectal cancer patients
Fouad, M. A., Salem, S., Osman, A. S., Badr, D. M., Hussein, M. M., Zekri, A. N., Hafez, H. F., Kamel, M. M., & Shouman, S. A. (2021) · International Journal of Immunopathology and Pharmacology · doi:10.1177/20587384211008332 · Cited by 2
Sarandria, N. (2021) · Journal of Cancer Therapy · doi:10.4236/jct.2021.1212059 · Cited by 2
“Also increase immune infiltrate—seen as higher immunogenicity with higher T-cell infiltrate—is seen in right sided CRCs (high MSI in right-sided) [11].”
BackgroundRetractedMolecular genetic testing in colon cancer: clinical aspects
Martianov, A. S., Kuligina, E. S., Romanko, A. A., & Имянитов, Е. Н. (2022) · Almanac of Clinical Medicine · doi:10.18786/072-0505-2022-50-002 · Cited by 2
Clinical Significance of Genetic Variants in Colon Cancer
Nakashidze, I., Petrović, N., Kedelidze, N., & Dariya, B. (2022) · Springer eBooks · doi:10.1007/978-3-030-72702-4_4 · Cited by 4
Wang, O., Shi, D., Li, Y., Zhou, X., Yan, H., & Yao, Q. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.912882 · Cited by 2
“Tumors in the right-sided and left-sided colon exhibit different molecular characteristics and histology (26).”
BackgroundVariants of creating heterotopic and orthotopic PDX models of human colorectal cancer
Kiblitskaya, A. A., Maksimov, A. Y., Гончарова, А. С., Nepomnyashchaya, Y. M., Zlatnik, Y. Y., Egorov, G. Y., Lukbanova, Y. A., Заикина, Е. В., & Volkova, А. V. (2022) · Bulletin of Siberian Medicine · doi:10.20538/1682-0363-2022-3-50-58 · Cited by 3
Ibrahiem, A. T., Eladl, E., Toraih, E. A., Fawzy, M. S., Abdelwahab, K. M., Elnaghi, K., Emarah, Z. A., Shaalan, A. A. M., Ehab, Z., & Soliman, N. (2023) · Diagnostics · doi:10.3390/diagnostics13020237 · Cited by 3
Liu, P.-G., Feng, P.-F., & Chen, X.-F. (2023) · World Journal of Clinical Cases · doi:10.12998/wjcc.v11.i5.1049 · Cited by 2
Laterality influence on gene expression of DNA damage repair in colorectal cancer
Oliveira-Silveira, J., Filippi‐Chiela, E. C., & Saffi, J. (2023) · Scientific Reports · doi:10.1038/s41598-023-42890-9 · Cited by 2
“Previous studies have shown right-side colon (RSC) tumors have a higher incidence of mutations in the DNA mismatch repair pathway and do not respond well to conventional chemotherapy 20 .”
Genetic profile of Chinese patients with small bowel cancer categorized by anatomic location
Shi, C., Ma, J., Zhang, T., Shi, Y., Duan, W., Huang, D., Zhang, H., & Zeng, Y. (2023) · BMC Medical Genomics · doi:10.1186/s12920-023-01736-z · Cited by 2
“The association of tumor location in CRC with molecular and clinical heterogeneity was widely demonstrated, especially the difference in genetic landscape between left and right CRC has been extensively and multi-dimensionally analyzed in the last decade [19–21].”
BackgroundA predictive model for early death in elderly colorectal cancer patients: a population-based study
Wang, Q., Shen, K., Fei, B., Luo, H., Li, R., Wang, Z., Wei, M., & Xie, Z. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1278137 · Cited by 2
Budianto, A., Andarini, S., Hariyanti, T., & Muslihah, N. (2024) · NURTURE · doi:10.55951/nurture.v18i2.614 · Cited by 2
Quang, H. N., Duc, L. N., Van, H. H., Hai, V. A., Trung, K. N., & Viet, T. L. (2024) · Journal of Clinical Laboratory Analysis · doi:10.1002/jcla.25112 · Cited by 2
Clinicopathological and radiological characteristics and prediction of survival in colon cancer
Kumar, A., & Kaw, P. K. (2025) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v17.i2.101516 · Cited by 2
Lucocq, J. E., Trinder, T., Homyer, K., Baig, H. Z., Patil, P., & Muthukumarasamy, G. (2025) · International Journal of Surgery · doi:10.1097/js9.0000000000002300 · Cited by 2
“There are significant genetic differences between right and left sided cancers, such as an association of microsatellite instability (MSI) with right sided cancers, compared to the chromosomal instability pathway mutations on the left [ 22 , 23 ] .”
Abrantes, A. M., Oliveira, R. C., Oliveiros, B., Cipriano, M. A., & Tralhão, J. G. (2025) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2025.01.004 · Cited by 4
Dolci, M., Civettini, I., Bagnoli, P. F., Toumi, W., Signorini, L., Crocchiolo, R., Maina, K. K., Perego, F., Ferrante, P., Scagnolari, C., et al. (2025) · Oncology · doi:10.1159/000543099 · Cited by 2
“Colorectal cancer (CRC) is the third most common tumor worldwide [1].”
Comparison of Risk Factors and Molecular Analysis of Right-Sided Colon and Left Sided Colon Cancer
Luisetto, M. (2019) · Advances in Cancer Research & Clinical Imaging · doi:10.33552/acrci.2019.02.000533 · Cited by 3
Danilov, M. A., Solov’yeva, O. N., Nikolaeva, A. O., & Alikhanov, R. (2022) · Nauka molodykh (Eruditio Juvenium) · doi:10.23888/hmj2022102187-194 · Cited by 2
Is it time to reduce the age of screening for colorectal cancer?
Frizelle, F., Waddell, O., & Glyn, T. (2023) · New Zealand Medical Journal · doi:10.26635/6965.e1580 · Cited by 2
Khan, D., Khan, A. K., Khan, S. D., Aman, M., Amin, A., Waseem, M., Kumari, U., Khan, F., Pervez, A., & Khan, A. (2023) · Annals of Medicine and Surgery · doi:10.1097/ms9.0000000000001241 · Cited by 2
“It can be characterized based on survival rate, progression of the disease, and metastatic spread([3]).”
BackgroundSeidl, S., Bischoff, P., Schaefer, A., Esser, M., Janzen, V., & Kovács, A. (2020) · Integrative Cancer Science and Therapeutics · doi:10.15761/icst.1000328 · Cited by 2
Wei, Z., Mao, R., Zhang, Y., Bi, X., Zhou, J., Li, Z., Huang, Z., Chen, X., Zhao, J., Zhao, H., et al. (2021) · Annals of Translational Medicine · doi:10.21037/atm-20-4286 · Cited by 2
“These discrepancies may be caused by the different embryonic origins and genetic profiles that account for distinct carcinogenesis and biological behavior (26-28).”
BackgroundIguchi, K., Mushiake, H., Fukushima, T., Rino, Y., & Masuda, M. (2021) · ANZ Journal of Surgery · doi:10.1111/ans.16638 · Cited by 2
“The distinction of RCC and LCC was based on embryological origins.(17,18) The segment extending from the caecum to the proximal two-thirds of the transverse colon derives from the midgut, whereas from the distal third of the transverse colon to the rectum is derived from the hindgut.”
BackgroundLijuan, Y., Wu, Y., Yangyanqiu, W., Xiaohui, H., Yunhai, W., & Han, S. (2021) · Human Immunology · doi:10.1016/j.humimm.2021.08.008 · Cited by 3
Cantero-Cid, R., Montalbán-Hernández, K. M., Guevara, J., Pascual‐Iglesias, A., Pulido, E., Casalvilla‐Dueñas, J. C., Marcano, C., Serrano, C. B., Valentín, J., Bonel-Pérez, G. C., et al. (2022) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v14.i1.295 · Cited by 2
Abdulkareem, F. B., Khramtsova, G. F., Odukoya, L. A., Badmos, K. B., Adedokun, T., Rotimi, O., Ibraheem, A. F., Khramtsov, A., Sveen, L., Hurley, I. W., et al. (2021) · Nigerian Journal of Gastroenterology and Hepatology · doi:10.4103/njgh.njgh_1_22 · Cited by 2
Sud, R., Viswanath, S., Mujeeb, V. R., Jaiswal, P., & Gupta, S. K. (2021) · Clinical Cancer Investigation Journal · doi:10.51847/g9cu0t74bi8904 · Cited by 2
Koizumi, K., Domoto, T., Minamoto, T., Kazuhito, K., & Nakajima, H. (2023) · International Journal of Oncology · doi:10.3892/ijo.2023.5540 · Cited by 1
Shilika, E. P., Siyumbwa, S., Mwale, M., & Julius, P. (2022) · Medical Journal of Zambia · doi:10.55320/mjz.49.2.1113 · Cited by 1
Mahmoud, A., Gomaa, W., & Eltiby, D. M. (2024) · International Journal of Medical Arts · doi:10.21608/ijma.2023.216865.1699 · Cited by 1
“To develop effective treatment strategies and improve treatment options, it is crucial to consider right-sided and left-sided tumors as distinct entities and develop treatment plans that take into account the differences between these tumors [37] .”
BackgroundCorrelation of red cell distribution width with tumor location and stage for colorectal cancer
Prasetyo, D. K., Sampetoding, S., Kusuma, M. I., Zainuddin, A. A., & Faruk, M. (2024) · Chirurgia · doi:10.23736/s0394-9508.23.05584-5 · Cited by 1
Ostojić, M., Đurić, A., Živić, K., & Grahovac, J. (2024) · PLoS ONE · doi:10.1371/journal.pone.0299685 · Cited by 1
“In addition, there is increasing evidence that COAD shows substantial differences in patient outcome depending on its origin: on the right or the left side of the colon [51].”
Liu, Q., Wang, X., Engstrand, L., Sadr‐Azodi, O., Fall, K., & Brusselaers, N. (2024) · BMJ Open · doi:10.1136/bmjopen-2023-079591 · Cited by 2
“28 28 29 Additionally, we used the less popular histamine-2 receptor antagonists (H 2 RAs) as active comparators in the supplementary analysis to minimise confounding- by-indication, as they share similar indications with PPIs and were used for treating gastric acid-related disorders before the…”
The pathological significance of HRAS gene mutation in colorectal cancer patients in Erbil province
Dizayee, S. (2024) · Zanco Journal of Medical Sciences · doi:10.15218/zjms.2024.28 · Cited by 1
Işık, D., & Kınıkoğlu, O. (2024) · Cureus · doi:10.7759/cureus.75046 · Cited by 1
Molecular Mosaics: Unveiling Heterogeneity in Synchronous Colorectal Cancers
Lee, H. G., Kim, Y., Kim, M., Kim, Y. W., Jun, S., Kim, D., Park, I. J., & Hong, S. (2025) · Cancer Research and Treatment · doi:10.4143/crt.2024.947 · Cited by 2
Egbuchiem, A. N., Okobi, O. E., Odutola, O. D., Igbenabor, C. A., Okey-Ndeche, U. N., Omotunde, O., Ayantoyinbo, T., Abonyi, O. C., Oghotuoma, O. O., Nnabude, O. H., et al. (2025) · Cureus · doi:10.7759/cureus.84530 · Cited by 1
“The pathogenesis of CRC varies by the anatomical location of the tumor, with distinct molecular characteristics and histological features observed between right-sided and left-sided colon cancers [7].”
Reich, J., Russo, M., Maddah, M., & Lau, K. N. (2025) · Contemporary surgical clerkships · doi:10.1007/978-3-031-85732-4_13 · Cited by 1
Yu, S., Fu, M., Wang, Y., Lin, L., Ji, S., Du, F., Song, L., Wang, M., Zhai, Y., Zhao, J., et al. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1584424 · Cited by 1
“Previous research has shown that DNA mismatch repair pathways frequently occurred in colon tumors located on the right side (23).”
Abu‐Freha, N., Hayadri, A., Sanalla, N., Ganayem, R., Abu-Ganim, B., Ganim, A. A., Reshef, A., Weissmann, S., & Hozaeel, W. (2025) · European Journal of Cancer Prevention · doi:10.1097/cej.0000000000000994 · Cited by 1
Maguire, B., Prehn, J. H. M., & Burke, J. P. (2025) · American Journal of Clinical Pathology · doi:10.1093/ajcp/aqaf124 · Cited by 2
“,24 Meta-analysis In this study, SATB2 loss was associated with several clinicopathologic features linked to chemotherapy resistance, including right-sided location, 32 histologic grade, mucinous histology, 33 MSI status, 34 and BRAF mutation.”
Sawaguchi, H., Uehara, T., Iwaya, M., Asaka, S., Nakajima, T., Komamura, S., Imamura, S., Iwaya, Y., Sugenoya, S., Kitazawa, M., et al. (2026) · Cancers · doi:10.3390/cancers18030482 · Cited by 1
“The predominance of PBK expression in right-sided tumors also aligns with previous findings that dMMR and immune-rich transcriptional signatures are more frequent in the right colon [41,42].”
Tsunematsu, M., Haruki, K., Yanamoto, K., Takehana, T., Ishizaki, S., Yanagaki, M., Shirai, Y., Furukawa, K., Onda, S., & Ikegami, T. (2026) · Annals of Gastroenterological Surgery · doi:10.1002/ags3.70190 · Cited by 1
“This anatomical alteration results in sustained exposure of the proximal colon to secondary bile acids, such as deoxycholic acid, which exert their carcinogenic effects including DNA damage, oxidative stress, and tumor progression [3, 6–8, 12, 13].”
InfluentialLopes, J. L., Soares, A. S. S., Mendes, B., Tomada, E. P., Cunha, M., Morán-Fernández, L., Amorim, E., Azevedo, J., & Amjad, P. (2026) · International Journal of Colorectal Disease · doi:10.1007/s00384-026-05103-z · Cited by 1
“Despite these concerns, previous evaluations of CT accuracy have rarely differentiated between right-and left-sided colon cancers, which differ markedly in epidemiology, molecular profile, metastatic patterns, and outcomes [16–22].”
Trinh, H. N., Phạm, Q. T., Phong, N., Ly, T. H., Ho, Q., Vu, H. V., Kha, V., & Ngo, Q. (2026) · Cancer Management and Research · doi:10.2147/cmar.s587649 · Cited by 1
“23 From comparison and regression analyses, we found that colorectal cancers with dMMR, especially dMutL, were associated with histopathologic grade and pTNM stage, which were more common in high-grade and early stages.”
Jin, C., Liu, H., Wu, Z., Hu, Y., Cui, Y., Guo, R., & Li, H. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1830436 · Cited by 1
“For example, right-sided lesions may differ from distal lesions in baseline immune tone and molecular context (61, 62); small or super fi cially sampled lesions may underrepresent stromal or invasive-margin compartments; and different analytic platforms such as conventional immunohistochemistry,…”
The Effect of Anti-Inflammatory Drugs on the Incidence of Colorectal Cancer
Misiak, M., Maciejowska, A., Pałęga, M., Burek, R., Gołda, A., Dworak, M., Pawuła-Prgomet, B., Forysiński, K., & Miłek, T. (2026) · Pharmaceutics · doi:10.3390/pharmaceutics18060643 · Cited by 1
Chen, J., Zhao, J., Zhang, X., & Zhu, H. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1768252 · Cited by 1
Jing, W., Qin, L., Zhang, X.-H., Pan, F., Ren, R.-R., Li, Y., Zhang, Y., Peng, L.-H., Wang, Z.-K., & Zhang, X.-L. (2026) · World Journal of Gastroenterology · doi:10.3748/wjg.121267 · Cited by 1
Liu, L., 陈颖君, Guo, M., Yun, F., Li, X., Chen, L., Li, Y. M., & Li, F. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1782130 · Cited by 1
Baig, R., Gosavi, R., & Wilkins, S. (2026) · Updates in Surgery · doi:10.1007/s13304-026-02772-x · Cited by 1
Genetic Ancestry and Colorectal Cancer in the All of Us Dataset
Chatzipanagiotou, O. P., Charalampous, C. M., Cordle, A., Elemosho, A., Alizai, Q., Mevawalla, A., Arena, L., Ejaz, R., & Pawlik, T. M. (2026) · JAMA Network Open · doi:10.1001/jamanetworkopen.2026.28789 · Cited by 1
Modeling human tumor evolution in mice
Watt, D. M., Mitchell, L. E., Etheridge, S. L., Dunne, P. D., Murphy, D. J., & Blyth, K. (2026) · STAR Protocols · doi:10.1016/j.xpro.2026.104872 · Cited by 1
“…activating Braf mutations with deletion of Alk5 , 14 and loss of Trp53 15 which has recapitulated several key features of right-sided CRC, including proximal tumor location and molecular characteristics associated with BRAF-mutant disease, 16 accurately modelling an important clinical subtype.”
Jugović, D., Vukelić-Nikolić, M. Đ., Madić, V., Branković, L., Milićević, R., Stanojević, G., & Vasiljevic, P. J. (2021) · Revista română de medicină de laborator · doi:10.2478/rrlm-2021-0035 · Cited by 2
RETRACTED: The Sarandria Score—Discussion of a New Scoring System in Clinical Medical Oncology
Sarandria, N. (2022) · International Journal of Clinical Medicine · doi:10.4236/ijcm.2022.133010 · Cited by 1
“There is chronic inflammation in the tumor [9] [10] [11] [12] [13] and an abundance of neutrophils.”
BackgroundRetractedOhno, Y., Kasahara, K., Nagakawa, Y., Katsumata, K., Tsuchida, A., & Matsubayashi, J. (2021) · Nihon Gekakei Rengo Gakkaishi (Journal of Japanese College of Surgeons) · doi:10.4030/jjcs.46.138 · Cited by 1
Utilising Proteomics and Organoid Cultures for Predicting Treatment Response in Colorectal Cancer
Micallef, I., & Baron, B. (2022) · IntechOpen eBooks · doi:10.5772/intechopen.106028 · Cited by 2
Sijmons, J., Zamaray, B., Veld, J. V., Warps, A. K., Dekker, J. W. T., Tuynman, J. B., van Westreenen, H. L., Consten, E. C. J., & Tanis, P. J. (2024) · Journal of Gastrointestinal Cancer · doi:10.1007/s12029-023-01010-6 · Cited by 1
Sánchez-Herrero, S., Tondar, A., Bernabeu, E. P., Calvet, L., & Juan, A. A. (2024) · BioMedInformatics · doi:10.3390/biomedinformatics4010041 · Cited by 1
“The location of the colorectal tumor is a crucial factor in disease progression and overall survival [59].”
BackgroundBananzadeh, A., Shojaei‐Zarghani, S., Bahadori, A. R., & Safarpour, A. R. (2024) · Shiraz E-Medical Journal · doi:10.5812/semj-150628 · Cited by 1
Muñoz, R. A., Miranda, F. J., Ramírez, A., Regalado, D. L., Ortiz, J. C., Gallardo, G., & Pizarro, S. (2025) · Revista de Gastroenterología de México · doi:10.1016/j.rgmx.2024.11.009 · Cited by 3
Meng, N., Wang, Z., Peng, Y., Wang, X., Yue, W., Wang, L. L., & Ma, W. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1545082 · Cited by 3
Muñoz, R. A., Miranda, F. J., Ramírez, A. A., Regalado, D. L., Ortiz, J. C., Gallardo, G., & Pizarro, S. (2025) · Revista de Gastroenterología de México (English Edition) · doi:10.1016/j.rgmxen.2025.09.001 · Cited by 1
Colebunders, J., Mullebrouck, B., Liégeois, V., Peeters, M., Vanhoutte, G., Damme, N. V., Janssens, K., & Vandamme, T. (2025) · The Oncologist · doi:10.1093/oncolo/oyaf317 · Cited by 1
Biomarkers in colon cancer and its clinical implications
Pavithran, K., & Srinivasalu, V. K. (2020) · Journal of Current Oncology · doi:10.4103/jco.jco_38_20 · Cited by 1
Hetrick, Y. M., Fesseha, M., & Hong, M. Y. (2021) · Journal of Functional Foods · doi:10.1016/j.jff.2021.104667 · Cited by 1
Metadata
- Authors
- Baran, B., Mert Ozupek, N., Yerli Tetik, N., Acar, E., Bekcioglu, O., & Baskin, Y.
- Affiliations
- Dokuz Eylül University (TR)
- ORCID
- Acar, Emine
- Venue
- Gastroenterology Research
- Publisher
- Elmer Press, Inc.
- Published
- 2018
- Volume
- 11
- Issue
- 4
- Pages
- 264-273
- ISSN
- 1918-2805 (ISSN-L)
- 1918-2813
- PMC
- PMC6089587
- OpenAlex
- W2887365295
- Cited by
- 553
- References
- 113
- Citations by year
- 2026: 62 · 2025: 59 · 2024: 117 · 2023: 76 · 2022: 66 · 2021: 90 · 2020: 56 · 2019: 25 · 2018: 2
- FWCI
- 4.52
- Type
- journal article
- Language
- en
- Open access
- diamond
- doi.org
- Licence
- cc-by-nc
- Locations
- Gastroenterology Research (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Health Sciences › Medicine › Oncology › Colorectal Cancer Surgical Treatments
- Health Sciences › Medicine › Pathology and Forensic Medicine › Genetic factors in colorectal cancer
- Keywords
- left-sided colorectal cancer, right-sided colorectal cancer, tumor location, mismatch repair deficiency, chromosomal instability, KRAS mutation, APC mutation, PIK3CA mutation, TP53 mutation, adjuvant chemotherapy, 5-fluorouracil, anti-EGFR therapy, immunotherapy, prognosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.